$100 million investment in Kansas manufacturer

Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, New Jersey, recently announced an investment of $100 million in facility expansion and enhancement efforts in its U.S. manufacturing site in DeSoto, Kansas. Investments to the site include a technological expansion of the vaccine production facility, which will come on line this year, plus an additional investment of $66 million that will provide for added enhancement capabilities to be realized over the coming years.

The DeSoto site develops and manufactures a broad portfolio of vaccines for swine, cattle and equine with key technologies in research and development, manufacturing and quality operations. Particularly, the site houses large-scale fermentation and cell culture, blending and filling operations and packaging, along with monoclonal antibody manufacturing for companion animals.